• Executive Summary o Market Overview • Market Landscape o Market ecosystem o Value chain analysis • Market Sizing o Market definition o Market segment analysis o Market size 2020 o Market outlook: Forecast for 2020 - 2025 • Five Forces Analysis o Five forces summary o Bargaining power of buyers o Bargaining power of suppliers o Threat of new entrants o Threat of substitutes o Threat of rivalry o Market condition • Market Segmentation by Type o Market segments o Comparison by Type o Small molecules - Market size and forecast 2020-2025 o Biologics - Market size and forecast 2020-2025 o Market opportunity by Type • Customer landscape • Geographic Landscape o Geographic segmentation o Geographic comparison o North America - Market size and forecast 2020-2025 o Europe - Market size and forecast 2020-2025 o Asia - Market size and forecast 2020-2025 o ROW - Market size and forecast 2020-2025 o Key leading countries o Market opportunity by geography o Market drivers o Market challenges o Market trends • Vendor Landscape o Competitive scenario o Vendor landscape o Landscape disruption • Vendor Analysis o Vendors covered o Market positioning of vendors o Bristol-Myers Squibb Co. o Eisai Co. Ltd. o Helsinn Healthcare SA o Hikma Pharmaceuticals Plc o Horizon Therapeutics Plc o Kyowa Kirin Co. Ltd. o Merck & Co. Inc. o Pfizer Inc. o Seagen Inc. o Takeda Pharmaceutical Co. Ltd. • Appendix o Scope of the report o Currency conversion rates for US$ o Research methodology o List of abbreviations Exhibit • 1: Key Finding 1 • 2: Key Finding 2 • 3: Key Finding 3 • 4: Key Finding 5 • 5: Key Finding 6 • 6: Key Finding 7 • 7: Key Finding 8 • 8: Parent market • 9: Market characteristics • 10: Offerings of vendors included in the market definition • 11: Market segments • 12: Global - Market size and forecast 2020 - 2025 ($ million) • 13: Global market: Year-over-year growth 2020 - 2025 (%) • 14: Five forces analysis 2020 & 2025 • 15: Bargaining power of buyers • 16: Bargaining power of suppliers • 17: Threat of new entrants • 18: Threat of substitutes • 19: Threat of rivalry • 20: Market condition - Five forces 2020 • 21: Type - Market share 2020-2025 (%) • 22: Comparison by Type • 23: Small molecules - Market size and forecast 2020-2025 ($ million) • 24: Small molecules - Year-over-year growth 2020-2025 (%) • 25: Biologics - Market size and forecast 2020-2025 ($ million) • 26: Biologics - Year-over-year growth 2020-2025 (%) • 27: Market opportunity by Type • 28: Customer landscape • 29: Market share by geography 2020-2025 (%) • 30: Geographic comparison • 31: North America - Market size and forecast 2020-2025 ($ million) • 32: North America - Year-over-year growth 2020-2025 (%) • 33: Europe - Market size and forecast 2020-2025 ($ million) • 34: Europe - Year-over-year growth 2020-2025 (%) • 35: Asia - Market size and forecast 2020-2025 ($ million) • 36: Asia - Year-over-year growth 2020-2025 (%) • 37: ROW - Market size and forecast 2020-2025 ($ million) • 38: ROW - Year-over-year growth 2020-2025 (%) • 39: Key leading countries • 40: Market opportunity by geography ($ million) • 41: Impact of drivers and challenges • 42: Vendor landscape • 43: Landscape disruption • 44: Industry risks • 45: Vendors covered • 46: Market positioning of vendors • 47: Bristol-Myers Squibb Co. - Overview • 48: Bristol-Myers Squibb Co. - Product and service • 49: Bristol-Myers Squibb Co. - Key offerings • 50: Bristol-Myers Squibb Co. - Key customers • 51: Bristol-Myers Squibb Co. - Segment focus • 52: Eisai Co. Ltd. - Overview • 53: Eisai Co. Ltd. - Business segments • 54: Eisai Co. Ltd. - Key offerings • 55: Eisai Co. Ltd. - Key customers • 56: Eisai Co. Ltd. - Segment focus • 57: Helsinn Healthcare SA - Overview • 58: Helsinn Healthcare SA - Product and service • 59: Helsinn Healthcare SA - Key offerings • 60: Helsinn Healthcare SA - Key customers • 61: Helsinn Healthcare SA - Segment focus • 62: Hikma Pharmaceuticals Plc - Overview • 63: Hikma Pharmaceuticals Plc - Business segments • 64: Hikma Pharmaceuticals Plc - Key offerings • 65: Hikma Pharmaceuticals Plc - Key customers • 66: Hikma Pharmaceuticals Plc - Segment focus • 67: Horizon Therapeutics Plc - Overview • 68: Horizon Therapeutics Plc - Business segments • 69: Horizon Therapeutics Plc - Key offerings • 70: Horizon Therapeutics Plc - Key customers • 71: Horizon Therapeutics Plc - Segment focus • 72: Kyowa Kirin Co. Ltd. - Overview • 73: Kyowa Kirin Co. Ltd. - Business segments • 74: Kyowa Kirin Co. Ltd. - Key offerings • 75: Kyowa Kirin Co. Ltd. - Key customers • 76: Kyowa Kirin Co. Ltd. - Segment focus • 77: Merck & Co. Inc. - Overview • 78: Merck & Co. Inc. - Business segments • 79: Merck & Co. Inc. - Key offerings • 80: Merck & Co. Inc. - Key customers • 81: Merck & Co. Inc. - Segment focus • 82: Pfizer Inc. - Overview • 83: Pfizer Inc. - Business segments • 84: Pfizer Inc. - Key offerings • 85: Pfizer Inc. - Key customers • 86: Pfizer Inc. - Segment focus • 87: Seagen Inc. - Overview • 88: Seagen Inc. - Business segments • 89: Seagen Inc. - Key offerings • 90: Seagen Inc. - Key customers • 91: Seagen Inc. - Segment focus • 92: Takeda Pharmaceutical Co. Ltd. - Overview • 93: Takeda Pharmaceutical Co. Ltd. - Product and service • 94: Takeda Pharmaceutical Co. Ltd. - Key offerings • 95: Takeda Pharmaceutical Co. Ltd. - Key customers • 96: Takeda Pharmaceutical Co. Ltd. - Segment focus • 97: Currency conversion rates for US$ • 98: Research Methodology • 99: Validation techniques employed for market sizing • 100: Information sources • 101: List of abbreviations

Bristol-Myers Squibb Co., Eisai Co. Ltd., Helsinn Healthcare SA, Hikma Pharmaceuticals Plc, Horizon Therapeutics Plc, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Pfizer Inc., Seagen Inc., Takeda Pharmaceutical Co. Ltd.